Resources Archive - Page 23 of 48

AACR 2024 Posters: Sneak Peek

AACR 2024 Sneak Peek | Your All-In-One Guide to WuXi Biology’s Latest Advances in Cancer Research The American Association for...

PROTAC Optimization Strategies

What if a constructed PROTAC with a confirmed high-affinity warhead doesn’t work as expected? That means we need to take...

T-DXd Resistant Tumor Models with ABCG2

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

OncoWuXi Express: Adenovirus Vaccine AD5-HPV Inhibits Tumor Growth by Stimulating Immunity

OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well...

Rare Disease Therapeutics: Accelerating Development and Improving Access

Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, has led to progress in...

Addition of Covalent Warhead and DEL-Generated Hit Fragmentation Empower FBDD

Fragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds. At the...

Establishment of EGFR TKI-Resistant Tumor Models

Despite improvement in clinical outcomes observed with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), long-term...

iMN041: Prodrug with a Unique Antitumor Immune Response

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses...

DNA-Compatible Cyclizations

The recent publication in the journal Organic Letters, ‘DNA-Compatible Cyclization Reaction to Access 1,3,4-Oxadiazoles & 1,2,4-Triazoles‘ by our WuXi Biology...

Knowledge Library